Navigation Links
MPM Capital Leads Investment in Proteon Therapeutics

Dr. Steven St. Peter Named to Proteon Board of Directors

KANSAS CITY, Mo., March 5 /PRNewswire/ -- MPM Capital, one of the world's largest life sciences-dedicated venture capital investors, announced today that it is the lead investor in a $38 million Series B equity financing of Proteon Therapeutics. In addition, Dr. Steven St. Peter, Managing Director of MPM Capital, has been named to the Proteon Therapeutics Board of Directors.

Proteon recently initiated a Phase 1/2 clinical trial of its lead product, PRT-201. PRT-201 is a recombinant human elastase that is being studied for its ability to improve arteriovenous fistula (AVF) surgery outcomes in patients requiring chronic hemodialysis.

"MPM continues to be very impressed with Proteon and the progress that the company has made," said Dr. Steven St. Peter. "In addition, this marks the first investment by MPM in a company with a substantial Kansas City presence. We have long followed the positive developments in the Kansas City area life sciences sector, and this investment affirms our view that attractive opportunities originate there."

Over the last several years, Dr. Steven St. Peter has worked informally with the Kansas City Area Life Sciences Institute in an advisory capacity. In addition, he currently serves as a member of the Kansas Bioscience Authority's Heartland BioVentures Advisory Board. Originally from Wichita, Dr. St. Peter has a B.A. in Chemistry from the University of Kansas. He completed his Doctor of Medicine at Washington University in St. Louis and his residency and fellowship at the Hospital of the University of Pennsylvania.

"Proteon is very pleased to have attracted the interest of MPM Capital, one of the world's premier healthcare venture capital firms," said F. Nicholas Franano, M.D., Chief Scientific Officer and founder of Proteon Therapeutics. "MPM's understanding of the life sciences industry makes them an ideal investor. In addition, I have known and worked with Steven St. Peter for over 20 years and am excited about the contribution he will make to our board of directors and the future direction of our company."

In addition to MPM Capital, the other new investor in this round of financing is the Vectis Healthcare & Life Sciences Fund. MPM and Vectis have a strong and deep relationship.

Tim Noyes, CEO of Proteon, said, "Proteon welcomes these additions to our already strong investor base. This financing will allow us to fund very significant clinical development in a field that needs better solutions."

About MPM Capital

MPM Capital is one of the world's largest dedicated investors in the life sciences. With offices in Boston and San Francisco, the firm manages committed capital in excess of $2 billion. MPM Capital has a deep and experienced team capable of investing from early-stage to late-stage which positions it to invest across the full spectrum of healthcare innovation. For additional information, visit

About Proteon Therapeutics

Proteon Therapeutics, Inc. is a privately held biopharmaceutical company developing novel, first-in-class pharmaceuticals to address the critical medical needs of patients with kidney and vascular diseases. The company is headquartered in Waltham, Mass., and has research facilities in Kansas City, Mo. For additional information, visit

Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Matrixx Initiatives, Inc. to Present at the Roth Capital Partners 2007 New York Conference
2. AtriCure to Present at Roth Capital Partners 2007 New York Conference
3. Doctors and medical ethicist discuss whether doctors should participate in capital punishment
4. Doctors and Medical Ethicist Discuss Whether Doctors Should Participate in Capital Punishment
5. Osteotech to Present at First Albany Capitals Regenerative Technologies Conference in New York
6. iCAD to Present at Americas Growth Capital 4th Annual Emerging Growth Conference
7. Pharsight Files Application for Nasdaq Capital Market Listing
8. Advanced Life Sciences Joins NASDAQ Capital Market
9. Foundation Venture Capital Group, LLC Invests in Start Up Committed to Breast Cancer Diagnostics
10. Bally Total Fitness Emerges From Chapter 11 and Closes Transaction with Harbinger Capital Partners Funds
11. Caxton-Iseman Capital Acquires Conney Safety Products, LLC
Post Your Comments:
(Date:10/13/2017)... , ... October 13, 2017 , ... Global Healthcare Management’s ... Alexandria Park in Milford, NJ. This free event, sponsored by Global Healthcare Management’s ... The fun run is geared towards children of all ages; it is a ...
(Date:10/13/2017)... , ... October 13, 2017 , ... ... and Agile Software Development, has been awarded a contract by the Center for ... Agreement (BPA) aims to accelerate the enterprise use of Agile methodologies in a ...
(Date:10/12/2017)... ... October 12, 2017 , ... First Healthcare Compliance ... management, will showcase a range of technology and learning solutions at the 68th ... and Expo to be held October 14–18, 2017 at the Mandalay Bay Resort ...
(Date:10/12/2017)... WAUSAU, Wis. (PRWEB) , ... October 12, 2017 ... ... formulated standard products to meet the demand of today’s consumer and regulatory authorities ... team of probiotic experts and tested to meet the highest standard. , ...
(Date:10/12/2017)... ... ... Asante, a nationally recognized health system in southern Oregon, ... health joint venture through an agreement, effective October 1, 2017, to create AccentCare ... company with Asante, delivering clinically integrated care, for the past eight years. This ...
Breaking Medicine News(10 mins):
(Date:9/28/2017)... WASHINGTON , Sept. 28, 2017 Cohen ... to advance the use of wearable and home sensors ... brain disorders. Early Signal Foundation, a nonprofit organization focused ... populations, will provide an affordable analytical system to record ... ...
(Date:9/27/2017)... NEW YORK , Sept. 27, 2017  DarioHealth Corp. (NASDAQ: DRIO), ... solutions, today announced that its MyDario product is expected to appear on ... for when The Dr. Oz Show airs in your area: ... The nine-time Emmy award-winning, The Dr. ... ...
(Date:9/25/2017)... , Sept. 25, 2017  EpiVax, Inc., ... vaccine design, and immune-engineering today announced the launch ... the development of personalized therapeutic cancer vaccines. EpiVax ... provided exclusive access to enabling technologies to the ... MBA will lead EpiVax Oncology as Chief Executive ...
Breaking Medicine Technology: